l impact • co-administration of calquence with a strong cyp3a inducer (rifampin) decreased acalabrutinib plasma concentrations [see clinical pharmacology (12.3) ] . • decreased acalabrutinib concentrations may reduce calquence activity. prevention or management • avoid co-administration of strong cyp3a inducers with calquence. • if a strong cyp3a inducer cannot be avoided, increase the acalabrutinib dose to 200 mg approximately every 12 hours. gastric acid reducing agents clinical impact • co-administration of calquence with a proton pump inhibitor, h2-receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations [ see clinical pharmacology (12.3) ] . • decreased acalabrutinib concentrations may reduce calquence activity. • if treatment with a gastric acid reducing agent is required, consider using a h2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). prevention or management antacids separate dosing by at least 2 hours [see recommended dosage for drug interactions (2.3) ] . h2-receptor antagonists take calquence 2 hours before taking the h2-receptor antagonist [see recommended dosage for drug interactions (2.3) ]. proton pump inhibitors avoid co-administration. due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with calquence. • cyp3a inhibitors: avoid co-administration with strong cyp3a inhibitors. dose adjustments may be recommended. (2.3 , 7 , 12.3) • cyp3a inducers: avoid co-administration with strong cyp3a inducers. dose adjustments may be recommended. (2.3 , 7 , 12.3) • gastric acid reducing agents: avoid co-administration with proton pump inhibitors (ppis). stagger dosing with h2-receptor antagonists and antacids. (2.4 , 7 , 12.3)

ce is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll).

occurred in the absence of grade 3 or 4 neutropenia, with neutropenic infection reported in 1.9% of all patients. opportunistic infections in recipients of calquence have included, but are not limited to, hepatitis b virus reactivation, fungal pneumonia, pneumocystis jiroveci pneumonia, epstein-barr virus reactivation, cytomegalovirus, and progressive multifocal leukoencephalopathy (pml). consider prophylaxis in patients who are at increased risk for opportunistic infections. monitor patients for signs and symptoms of infection and treat promptly. 5.2 hemorrhage fatal and serious hemorrhagic events have occurred in patients with hematologic malignancies treated with calquence. major hemorrhage (serious or grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3.0% of patients, with fatal hemorrhage occurring in 0.1% of 1029 patients exposed to calquence in clinical trials. bleeding events of any grade, excluding bruising and petechiae, occurred in 22% of patients. use of antithrombotic agents concomitantly with calquence may further increase the risk of hemorrhage. in clinical trials, major hemorrhage occurred in 2.7% of patients taking calquence without antithrombotic agents and 3.6% of patients taking calquence with antithrombotic agents. consider the risks and benefits of antithrombotic agents when co-administered with calquence. monitor patients for signs of bleeding. consider the benefit-risk of withholding calquence for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding. 5.3 cytopenias grade 3 or 4 cytopenias, including neutropenia (23%), anemia (8%), thrombocytopenia (7%), and lymphopenia (7%), developed in patients with hematologic malignancies treated with calquence. grade 4 neutropenia developed in 12% of patients. monitor complete blood counts regularly during treatment. interrupt treatment, reduce the dose, or discontinue treatment as warranted [see dose modifications for adverse reactions (2.4) ] . 5.4 second primary malignancies second primary malignancies, including skin cancers and other solid tumors, occurred in 12% of 1029 patients exposed to calquence in clinical trials. the most frequent second primary malignancy was skin cancer, reported in 6% of patients. monitor patients for skin cancers and advise protection from sun exposure. 5.5 atrial fibrillation and flutter grade 3 atrial fibrillation or flutter occurred in 1.1% of 1029 patients treated with calquence, with all grades of atrial fibrillation or flutter reported in 4.1% of all patients. the risk may be increased in patients with cardiac risk factors, hypertension, previous arrhythmias, and acute infection. monitor for symptoms of arrhythmia (e.g., palpitations, dizziness, syncope, dyspnea) and manage as appropriate.

information for recommended dosing. administer calquence prior to obinutuzumab when given on the same day. advise patients to swallow capsule whole with water. advise patients not to open, break or chew the capsules. calquence may be taken with or without food. if a dose of calquence is missed by more than 3 hours, it should be skipped and the next dose should be taken at its regularly scheduled time. extra capsules of calquence should not be taken to make up for a missed dose. 2.2 recommended dosage for hepatic impairment avoid administration of calquence in patients with severe hepatic impairment. dose modifications are not required for patients with mild or moderate hepatic impairment [see use in specific populations (8.6) and clinical pharmacology (12.3) ] . 2.3 recommended dosage for drug interactions dose modifications for use with cyp3a inhibitors or inducers these are described in table 1 [see drug interactions (7) ] . table 1: recommended dose modifications for use with cyp3a inhibitors or inducers cyp3a co-administered drug recommended calquence use inhibition strong cyp3a inhibitor avoid concomitant use. if these inhibitors will be used short-term (such as anti‑infectives for up to seven days), interrupt calquence. moderate cyp3a inhibitor 100 mg once daily. induction strong cyp3a inducer avoid concomitant use. if these inducers cannot be avoided, increase calquence dose to 200 mg approximately every 12 hours. concomitant use with gastric acid reducing agents proton pump inhibitors: avoid concomitant use [see drug interactions (7) ] . h2-receptor antagonists: take calquence 2 hours before taking a h2-receptor antagonist [see drug interactions (7) ] . antacids: separate dosing by at least 2 hours [see drug interactions (7) ] . 2.4 dose modifications for adverse reactions recommended dose modifications of calquence for grade 3 or greater adverse reactions are provided in table 2. table 2: recommended dose modifications for adverse reactions event adverse reaction occurrence dose modification (starting dose = 100 mg approximately every 12 hours) grade 3 or greater non-hematologic toxicities, grade 3 thrombocytopenia with bleeding, first and second interrupt calquence. once toxicity has resolved to grade 1 or baseline level, calquence may be resumed at 100 mg approximately every 12 hours. grade 4 thrombocytopenia or grade 4 neutropenia lasting longer than 7 days third interrupt calquence. once toxicity has resolved to grade 1 or baseline level, calquence may be resumed at a reduced frequency of 100 mg once daily. fourth discontinue calquence. adverse reactions graded by the national cancer institute common terminology criteria for adverse events (nci ctcae). refer to the obinutuzumab prescribing information for management of obinutuzumab toxicities.

the clinical trials of another drug and may not reflect the rates observed in practice. the data in the warnings and precautions reflect exposure to calquence 100 mg approximately every 12 hours in 1029 patients with hematologic malignancies. treatment includes calquence monotherapy in 820 patients in 6 trials, and calquence with obinutuzumab in 209 patients in 2 trials. among these recipients of calquence, 88% were exposed for at least 6 months and 79% were exposed for at least one year. in this pooled safety population, adverse reactions in ≥ 30% of 1029 patients were anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain. mantle cell lymphoma the safety data described in this section reflect exposure to calquence (100 mg approximately every 12 hours) in 124 patients with previously treated mcl in trial ly-004 [see clinical studies (14.1) ] . the median duration of treatment with calquence was 16.6 (range: 0.1 to 26.6) months. a total of 91 (73.4%) patients were treated with calquence for ≥ 6 months and 74 (59.7%) patients were treated for ≥ 1 year. the most common adverse reactions (≥ 20%) of any grade were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising. grade 1 severity for the non-hematologic, most common events were as follows: headache (25%), diarrhea (16%), fatigue (20%), myalgia (15%), and bruising (19%). the most common grade ≥ 3 non-hematological adverse reaction (reported in at least 2% of patients) was diarrhea. dose reductions and discontinuation due to any adverse reaction were reported in 1.6% and 6.5% of patients, respectively. tables 3 and 4 present the frequency category of adverse reactions observed in patients with mcl treated with calquence. table 3: non-hematologic adverse reactions in ≥ 5% (all grades) of patients with mcl in trial ly-004 body system adverse reactions per nci ctcae version 4.03. calquence monotherapy n=124 all grades (%) grade ≥ 3 (%) nervous system disorders headache 39 1.6 gastrointestinal disorders diarrhea 31 3.2 nausea 19 0.8 abdominal pain 15 1.6 constipation 15 - vomiting 13 1.6 general disorders fatigue 28 0.8 musculoskeletal and connective tissue disorders myalgia 21 0.8 skin and subcutaneous tissue disorders bruising bruising: includes all terms containing ‘bruise,’ ‘contusion,’ ‘petechiae,’ or ‘ecchymosis’ 21 - rash rash: includes all terms containing ‘rash’ 18 0.8 vascular disorders hemorrhage hemorrhage: includes all terms containing ‘hemorrhage’ or ‘hematoma’ 8 0.8 respiratory, thoracic and mediastinal disorders epistaxis 6 - table 4: hematologic adverse reactions reported in ≥ 20% of patients with mcl in trial ly-004 hematologic adverse reactions per nci ctcae version 4.03; based on laboratory measurements and adverse reactions. calquence monotherapy n=124 all grades (%) grade ≥ 3 (%) hemoglobin decreased 46 10 platelets decreased 44 12 neutrophils decreased 36 15 increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 4.8% of patients. chronic lymphocytic leukemia the safety data described below reflect exposure to calquence (100 mg approximately every 12 hours, with or without obinutuzumab) in 511 patients with cll from two randomized controlled clinical trials [see clinical studies (14.2) ] . the most common adverse reactions (≥ 30%) of any grade in patients with cll were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea. elevate-tn the safety of calquence plus obinutuzumab (calquence+g), calquence monotherapy, and obinutuzumab plus chlorambucil (gclb) was evaluated in a randomized, multicenter, open-label, actively controlled trial in 526 patients with previously untreated cll [see clinical studies (14.2) ] . patients randomized to the calquence+g arm were treated with calquence and obinutuzumab in combination for six cycles, then with calquence as monotherapy until disease progression or unacceptable toxicity. patients initiated obinutuzumab on day 1 of cycle 2, continuing for a total of 6 cycles. patient randomized to calquence monotherapy received calquence approximately every 12 hours until disease progression or unacceptable toxicity. the trial required age ≥ 65 years of age or 18 to < 65 years of age with a total cumulative illness rating scale (cirs) > 6 or creatinine clearance of 30 to 69 ml/min, hepatic transaminases ≤ 3 times upper limit of normal (uln) and total bilirubin ≤ 1.5 times uln, and allowed patients to receive antithrombotic agents other than warfarin or equivalent vitamin k antagonists. during randomized treatment, the median duration of exposure to calquence in the calquence+g and calquence monotherapy arms was 27.7 months (range 0.3 to 40 months), with 95% and 92% and 89% and 86% of patients with at least 6 months and 12 months of exposure, respectively. in the obinutuzumab and chlorambucil arm the median number of cycles was 6 with 84% of patients receiving at least 6 cycles of obinutuzumab, 70% of patients received at least 6 cycles of chlorambucil. eighty-five percent of patients in the calquence+g arm received at least 6 cycles of obinutuzumab. in the calquence+g and calquence monotherapy arms, fatal adverse reactions that occurred in the absence of disease progression and with onset within 30 days of the last study treatment were reported in 2% for each treatment arm, most often from infection. serious adverse reactions were reported in 39% of patients in the calquence+g arm and 32% in the calquence monotherapy arm, most often due to events of pneumonia (2.8% to 7%). in the calquence+g arm, adverse reactions led to treatment discontinuation in 11% of patients and a dose reduction of calquence in 7% of patients. in the calquence monotherapy arm, adverse reactions led to discontinuation in 10% and dose reduction in 4% of patients. tables 5 and 6 presents adverse reactions and laboratory abnormalities identified in the elevate-tn trial. table 5: common adverse reactions (≥ 15% any grade) with calquence in patients with cll (elevate-tn) body system adverse reaction per nci ctcae version 4.03 calquence plus obinutuzumab n=178 calquence monotherapy n=179 obinutuzumab plus chlorambucil n=169 all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) infections infection includes any adverse reactions involving infection or febrile neutropenia 69 22 includes 3 fatal cases in the calquence plus obinutuzumab arm, 3 fatal cases in the calquence monotherapy arm and 1 fatal case in the obinutuzumab plus chlorambucil arm 65 14 46 13 upper respiratory tract infection upper respiratory tract infection, nasopharyngitis and sinusitis 39 2.8 35 0 17 1.2 lower respiratory tract infection includes pneumonia, lower respiratory tract infection, bronchitis, bronchiolitis, tracheitis, and lung infection 24 8 18 4.5 7 1.8 urinary tract infection 15 1.7 15 2.8 5 0.6 blood and lymphatic system disorders derived from adverse reactions and laboratory data neutropenia includes neutropenia, neutrophil count decreased, and related laboratory data 53 37 23 13 78 50 anemia includes anemia, red blood cell count decreased, and related laboratory data 52 12 53 10 54 14 thrombocytopenia includes thrombocytopenia, platelet count decreased, and related laboratory data 51 12 32 3.4 61 16 lymphocytosis includes lymphocytosis, lymphocyte count increased, and related laboratory data 12 11 16 15 0.6 0.6 nervous system disorders headache 40 1.1 39 1.1 12 0 dizziness 20 0 12 0 7 0 gastrointestinal disorders diarrhea 39 4.5 35 0.6 21 1.8 nausea 20 0 22 0 31 0 musculoskeletal and connective tissue disorders musculoskeletal pain includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity and spinal pain 37 2.2 32 1.1 16 2.4 arthralgia 22 1.1 16 0.6 4.7 1.2 general disorders and administration site conditions fatigue includes asthenia, fatigue, and lethargy 34 2.2 23 1.1 24 1.2 skin and subcutaneous tissue disorders bruising includes bruise, contusion, and ecchymosis 31 0 21 0 5 0 rash includes rash, dermatitis, and other related terms 26 2.2 25 0.6 9 0.6 vascular disorders hemorrhage includes hemorrhage, hematoma, hemoptysis, hematuria, menorrhagia, hemarthrosis, and epistaxis 20 1.7 20 1.7 6 0 other clinically relevant adverse reactions (all grades incidence < 15%) in recipients of calquence (calquence in combination with obinutuzumab and monotherapy) included: • neoplasms: second primary malignancy (10%), non-melanoma skin cancer (5%) • cardiac disorders: atrial fibrillation or flutter (3.6%), hypertension (5%) • infection: herpesvirus infection (6%) table 6: select non-hematologic laboratory abnormalities (≥ 15% any grade), new or worsening from baseline in patients receiving calquence (elevate-tn) laboratory abnormality per nci ctcae version 4.03 excludes electrolytes calquence plus obinutuzumab n=178 calquence monotherapy n=179 obinutuzumab plus chlorambucil n=169 all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) uric acid increase 29 29 22 22 37 37 alt increase 30 7 20 1.1 36 6 ast increase 38 5 17 0.6 60 8 bilirubin increase 13 0.6 15 0.6 11 0.6 increases in creatinine 1.5 to 3 times the upper limit of normal occurred in 3.9% and 2.8% of patients in the calquence combination arm and monotherapy arm, respectively. ascend the safety of calquence in patients with relapsed or refractory cll was evaluated in a randomized, open-label study (ascend) [see clinical studies (14.2) ] . the trial enrolled patients with relapsed or refractory cll after at least one prior therapy and required hepatic transaminases ≤ 2 times upper limit of normal (uln), total bilirubin ≤ 1.5 times uln, and an estimated creatinine clearance ≥ 30 ml/min. the trial excluded patients having an absolute neutrophil count < 500/µl, platelet count < 30,000/µl, prothrombin time or activated partial thromboplastin time > 2 times uln, significant cardiovascular disease, or a requirement for strong cyp3a inhibitors or inducers. patients were allowed to receive antithrombotic agents other than warfarin or equivalent vitamin k antagonist. in ascend, 154 patients received calquence (100 mg approximately every 12 hours until disease progression or unacceptable toxicity), 118 received idelalisib (150 mg approximately every 12 hours until disease progression or unacceptable toxicity) with up to 8 infusions of a rituximab product, and 35 received up to 6 cycles of bendamustine and a rituximab product. the median age overall was 68 years (range: 32-90); 67% were male; 92% were white; and 88% had an ecog performance status of 0 or 1. in the calquence arm, serious adverse reactions occurred in 29% of patients. serious adverse reactions in > 5% of patients who received calquence included lower respiratory tract infection (6%). fatal adverse reactions within 30 days of the last dose of calquence occurred in 2.6% of patients, including from second primary malignancies and infection. in recipients of calquence, permanent discontinuation due to an adverse reaction occurred in 10% of patients, most frequently due to second primary malignancies followed by infection. adverse reactions led to dosage interruptions of calquence in 34% of patients, most often due to respiratory tract infections followed by neutropenia, and dose reduction in 3.9% of patients. selected adverse reactions are described in table 7 and non-hematologic laboratory abnormalities are described in table 8. these tables reflect exposure to calquence with median duration of 15.7 months with 94% of patients on treatment for greater than 6 months and 86% of patients on treatment for greater than 12 months. the median duration of exposure to idelalisib was 11.5 months with 72% of patients on treatment for greater than 6 months and 48% of patients on treatment for greater than 12 months. eighty-three percent of patients completed 6 cycles of bendamustine and rituximab product. table 7: common adverse reactions (≥ 15% any grade) with calquence in patients with cll (ascend) body system adverse reaction per nci ctcae version 4.03 calquence n=154 idelalisib plus rituximab product n=118 bendamustine plus rituximab product n=35 all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) infections infection includes any adverse reactions involving infection or febrile neutropenia 56 15 includes 1 fatal case in the calquence monotherapy arm and 1 fatal case in the idelalisib plus rituximab arm 65 28 49 11 upper respiratory tract infection upper respiratory tract infection, rhinitis and nasopharyngitis 29 1.9 26 3.4 17 2.9 lower respiratory tract infection includes pneumonia, lower respiratory tract infection, bronchitis, bronchiolitis, tracheitis, and lung infection 23 6 26 15 14 6 blood and lymphatic system disorders derived from adverse reaction and laboratory data neutropenia includes neutropenia, neutrophil count decreased, and related laboratory data 48 23 79 53 80 40 anemia includes anemia, red blood cell decreased, and related laboratory data 47 15 45 8 57 17 thrombocytopenia includes thrombocytopenia, platelet count decreased, and related laboratory data 33 6 41 13 54 6 lymphocytosis includes lymphocytosis, lymphocyte count increased and related laboratory data 26 19 23 18 2.9 2.9 nervous system disorders headache 22 0.6 6 0 0 0 gastrointestinal disorders diarrhea includes colitis, diarrhea, and enterocolitis 18 1.3 49 25 14 0 vascular disorders hemorrhage includes hemorrhage, hematoma, hemoptysis, hematuria, menorrhagia, hemarthrosis, and epistaxis 16 1.3 5 1.7 6 2.9 general disorders fatigue includes asthenia, fatigue, and lethargy 15 1.9 13 0.8 31 6 musculoskeletal and connective tissue disorders musculoskeletal pain includes back pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal discomfort, pain in extremity, myalgia, spinal pain and bone pain 15 1.3 15 1.7 2.9 0 other clinically relevant adverse reactions (all grades incidence < 15%) in recipients of calquence included: • skin and subcutaneous disorders: bruising (10%), rash (9%) • neoplasms: second primary malignancy (12%), non-melanoma skin cancer (6%) • musculoskeletal and connective tissue disorders: arthralgia (8%) • cardiac disorders: atrial fibrillation or flutter (5%), hypertension (3.2%) • infection: herpesvirus infection (4.5%) table 8: select non-hematologic laboratory abnormalities (≥ 10% any grade), new or worsening from baseline in patients receiving calquence (ascend) laboratory abnormality excludes electrolytes calquence n=154 idelalisib plus rituximab product n=118 bendamustine plus rituximab product n=35 all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) all grades (%) grade ≥ 3 (%) uric acid increase 15 15 11 11 23 23 alt increase 15 1.9 59 23 26 2.9 ast increase 13 0.6 48 13 31 2.9 bilirubin increase 13 1.3 16 1.7 26 11 per nci ctcae version 5

l impact • co-administration of calquence with a strong cyp3a inducer (rifampin) decreased acalabrutinib plasma concentrations [see clinical pharmacology (12.3) ] . • decreased acalabrutinib concentrations may reduce calquence activity. prevention or management • avoid co-administration of strong cyp3a inducers with calquence. • if a strong cyp3a inducer cannot be avoided, increase the acalabrutinib dose to 200 mg approximately every 12 hours. gastric acid reducing agents clinical impact • co-administration of calquence with a proton pump inhibitor, h2-receptor antagonist, or antacid may decrease acalabrutinib plasma concentrations [ see clinical pharmacology (12.3) ] . • decreased acalabrutinib concentrations may reduce calquence activity. • if treatment with a gastric acid reducing agent is required, consider using a h2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate). prevention or management antacids separate dosing by at least 2 hours [see recommended dosage for drug interactions (2.3) ] . h2-receptor antagonists take calquence 2 hours before taking the h2-receptor antagonist [see recommended dosage for drug interactions (2.3) ]. proton pump inhibitors avoid co-administration. due to the long-lasting effect of proton pump inhibitors, separation of doses may not eliminate the interaction with calquence. • cyp3a inhibitors: avoid co-administration with strong cyp3a inhibitors. dose adjustments may be recommended. (2.3 , 7 , 12.3) • cyp3a inducers: avoid co-administration with strong cyp3a inducers. dose adjustments may be recommended. (2.3 , 7 , 12.3) • gastric acid reducing agents: avoid co-administration with proton pump inhibitors (ppis). stagger dosing with h2-receptor antagonists and antacids. (2.4 , 7 , 12.3)

miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in a combined fertility and embryo-fetal development study in female rats, acalabrutinib was administered orally at doses up to 200 mg/kg/day starting 14 days prior to mating through gestational day [gd] 17. no effects on embryo-fetal development and survival were observed. the auc at 200 mg/kg/day in pregnant rats was approximately 9-times the auc in patients at the recommended dose of 100 mg approximately every 12 hours. the presence of acalabrutinib and its active metabolite were confirmed in fetal rat plasma. in an embryo-fetal development study in rabbits, pregnant animals were administered acalabrutinib orally at doses up to 200 mg/kg/day during the period of organogenesis (from gd 6-18). administration of acalabrutinib at doses ≥ 100 mg/kg/day produced maternal toxicity and 100 mg/kg/day resulted in decreased fetal body weights and delayed skeletal ossification. the auc at 100 mg/kg/day in pregnant rabbits was approximately 2-times the auc in patients at 100 mg approximately every 12 hours. in a pre- and postnatal development study in rats, acalabrutinib was administered orally to pregnant animals during organogenesis, parturition and lactation, at doses of 50, 100, and 150 mg/kg/day. dystocia (prolonged or difficult labor) and mortality of offspring were observed at doses ≥ 100 mg/kg/day. the auc at 100 mg/kg/day in pregnant rats was approximately 2-times the auc in patients at 100 mg approximately every 12 hours. underdeveloped renal papilla was also observed in f1 generation offspring at 150 mg/kg/day with an auc approximately 5-times the auc in patients at 100 mg approximately every 12 hours. 8.2 lactation risk summary no data are available regarding the presence of acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production. acalabrutinib and its active metabolite were present in the milk of lactating rats. due to the potential for adverse reactions in a breastfed child from calquence, advise lactating women not to breastfeed while taking calquence and for at least 2 weeks after the final dose. 8.3 females and males of reproductive potential pregnancy pregnancy testing is recommended for females of reproductive potential prior to initiating calquence therapy. contraception females calquence may cause embryo-fetal harm and dystocia when administered to pregnant women [see use in specific populations (8.1) ] . advise female patients of reproductive potential to use effective contraception during treatment with calquence and for at least 1 week following the last dose of calquence. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus. 8.4 pediatric use the safety and efficacy of calquence in pediatric patients have not been established. 8.5 geriatric use of the 929 patients with cll or mcl in clinical trials of calquence, 68% were 65 years of age or older, and 24% were 75 years of age or older. among patients 65 years of age or older, 59% had grade 3 or higher adverse reactions and 39% had serious adverse reactions. among patients younger than age 65, 45% had grade 3 or higher adverse reactions and 25% had serious adverse reactions. no clinically relevant differences in efficacy were observed between patients ≥ 65 years and younger. 8.6 hepatic impairment avoid administration of calquence in patients with severe hepatic impairment. the safety of calquence has not been evaluated in patients with moderate or severe hepatic impairment [see recommended dosage for hepatic impairment (2.2) and clinical pharmacology (12.3) ] .

al development study in female rats, acalabrutinib was administered orally at doses up to 200 mg/kg/day starting 14 days prior to mating through gestational day [gd] 17. no effects on embryo-fetal development and survival were observed. the auc at 200 mg/kg/day in pregnant rats was approximately 9-times the auc in patients at the recommended dose of 100 mg approximately every 12 hours. the presence of acalabrutinib and its active metabolite were confirmed in fetal rat plasma. in an embryo-fetal development study in rabbits, pregnant animals were administered acalabrutinib orally at doses up to 200 mg/kg/day during the period of organogenesis (from gd 6-18). administration of acalabrutinib at doses ≥ 100 mg/kg/day produced maternal toxicity and 100 mg/kg/day resulted in decreased fetal body weights and delayed skeletal ossification. the auc at 100 mg/kg/day in pregnant rabbits was approximately 2-times the auc in patients at 100 mg approximately every 12 hours. in a pre- and postnatal development study in rats, acalabrutinib was administered orally to pregnant animals during organogenesis, parturition and lactation, at doses of 50, 100, and 150 mg/kg/day. dystocia (prolonged or difficult labor) and mortality of offspring were observed at doses ≥ 100 mg/kg/day. the auc at 100 mg/kg/day in pregnant rats was approximately 2-times the auc in patients at 100 mg approximately every 12 hours. underdeveloped renal papilla was also observed in f1 generation offspring at 150 mg/kg/day with an auc approximately 5-times the auc in patients at 100 mg approximately every 12 hours.

electrophysiology the effect of acalabrutinib on the qtc interval was evaluated in a randomized, double-blind, double-dummy, placebo‑ and positive-controlled, 4-way crossover thorough qtc study in 48 healthy adult subjects. administration of a single dose of acalabrutinib that is the 4-fold maximum recommended single dose did not prolong the qtc interval to any clinically relevant extent (i.e., ≥ 10 ms). 12.3 pharmacokinetics acalabrutinib exhibits dose-proportionality, and both acalabrutinib and its active metabolite, acp-5862, exposures increase with dose across a dose range of 75 to 250 mg (0.75 to 2.5 times the approved recommended single dose) in patients with b-cell malignancies. at the recommended dose of 100 mg twice daily, the geometric mean (% coefficient of variation [cv]) daily area under the plasma drug concentration over time curve (auc24h) and maximum plasma concentration (cmax) for acalabrutinib were 1843 (38%) ng•h/ml and 563 (29%) ng/ml, respectively, and for acp-5862 were 3947 (43%) ng•h/ml and 451 (52%) ng/ml, respectively. absorption the geometric mean absolute bioavailability of acalabrutinib was 25%. median [min, max] time to peak acalabrutinib plasma concentrations (tmax) was 0.9 [0.5, 1.9] hours, and 1.6 [0.9, 2.7] hour for acp-5862. effect of food in healthy subjects, administration of a single 75 mg dose of acalabrutinib (0.75 times the approved recommended single dose) with a high-fat, high-calorie meal (approximately 918 calories, 59 grams carbohydrate, 59 grams fat, and 39 grams protein) did not affect the mean auc as compared to dosing under fasted conditions. resulting c max decreased by 73% and t max was delayed 1-2 hours. distribution reversible binding to human plasma protein was 97.5% for acalabrutinib and 98.6% for acp-5862. the in vitro mean blood-to-plasma ratio was 0.8 for acalabrutinib and 0.7 for acp-5862. the geometric mean (% cv) steady-state volume of distribution (vss) was approximately 101 (52%) l for acalabrutinib and 67 (32%) l for acp-5862. elimination the geometric mean (% cv) terminal elimination half-life (t1/2) was 1 (59%) hour for acalabrutinib and 3.5 (24%) hours for acp-5862. the geometric mean (%cv) apparent oral clearance (cl/f) was 71 (35%) l/hr for acalabrutinib and 13 (42%) l/hr for acp-5862. metabolism acalabrutinib is predominantly metabolized by cyp3a enzymes, and to a minor extent, by glutathione conjugation and amide hydrolysis, based on in vitro studies. acp-5862 was identified as the major active metabolite in plasma with a geometric mean exposure (auc) that was approximately 2- to 3-fold higher than the exposure of acalabrutinib. acp-5862 is approximately 50% less potent than acalabrutinib with regard to btk inhibition. excretion following administration of a single 100 mg radiolabeled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine, with less than 2% of the dose excreted as unchanged acalabrutinib in urine and feces. specific populations age, race, and body weight age (32 to 90 years), sex, race (caucasian, african american), and body weight (40 to 149 kg) did not have clinically meaningful effects on the pk of acalabrutinib and its active metabolite, acp-5862. renal impairment no clinically relevant pk difference was observed in patients with mild or moderate renal impairment (egfr ≥ 30 ml/min/1.73m2, as estimated by mdrd (modification of diet in renal disease equation)). acalabrutinib pk has not been evaluated in patients with severe renal impairment (egfr < 29 ml/min/1.73m2, mdrd) or renal impairment requiring dialysis. hepatic impairment the auc of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (child-pugh class a), 1.5-fold in subjects with moderate hepatic impairment (child-pugh class b) and 5.3-fold in subjects with severe hepatic impairment (child-pugh class c) compared to subjects with normal liver function. no clinically relevant pk difference in acp-5862 was observed in subjects with severe hepatic impairment (child-pugh class c) compared to subjects with normal liver function. no clinically relevant pk differences in acalabrutinib and acp-5862 were observed in patients with mild or moderate hepatic impairment (total bilirubin less and equal to upper limit of normal [uln] and ast greater than uln, or total bilirubin greater than uln and any ast) relative to patients with normal hepatic function (total bilirubin and ast within uln). drug interaction studies effect of cyp3a inhibitors on acalabrutinib co-administration with a strong cyp3a inhibitor (200 mg itraconazole once daily for 5 days) increased the acalabrutinib c max by 3.9-fold and auc by 5.1-fold in healthy subjects. physiologically based pharmacokinetic (pbpk) simulations with acalabrutinib and moderate cyp3a inhibitors (erythromycin, fluconazole, diltiazem) showed that co-administration increased acalabrutinib c max and auc approximately 2- to 3-fold. effect of cyp3a inducers on acalabrutinib co-administration with a strong cyp3a inducer (600 mg rifampin once daily for 9 days) decreased acalabrutinib c max by 68% and auc by 77% in healthy subjects. gastric acid reducing agents acalabrutinib solubility decreases with increasing ph. co-administration with an antacid (1 g calcium carbonate) decreased acalabrutinib auc by 53% in healthy subjects. co-administration with a proton pump inhibitor (40 mg omeprazole for 5 days) decreased acalabrutinib auc by 43%. in vitro studies metabolic pathways acalabrutinib is a weak inhibitor of cyp3a4/5, cyp2c8 and cyp2c9, but does not inhibit cyp1a2, cyp2b6, cyp2c19, cyp2d6, ugt1a1, and ugt2b7. acp-5862 is a weak inhibitor of cyp2c8, cyp2c9 and cyp2c19, but does not inhibit cyp1a2, cyp2b6, cyp2d6, cyp3a4/5, ugt1a1, and ugt2b7. acalabrutinib is a weak inducer of cyp1a2, cyp2b6 and cyp3a4; acp-5862 weakly induces cyp3a4. based on in vitro data and pbpk modeling, no interaction with cyp substrates is expected at clinically relevant concentrations. drug transporter systems acalabrutinib and its active metabolite, acp-5862, are substrates of p-glycoprotein (p-gp) and breast cancer resistance protein (bcrp). acalabrutinib is not a substrate of renal uptake transporters oat1, oat3, and oct2, or hepatic transporters oatp1b1, and oatp1b3. acp-5862 is not a substrate of oatp1b1 or oatp1b3. acalabrutinib and acp-5862 do not inhibit p-gp, oat1, oat3, oct2, oatp1b1, oatp1b3, and mate2-k at clinically relevant concentrations. acalabrutinib may increase exposure to co-administered bcrp substrates (e.g., methotrexate) by inhibition of intestinal bcrp. acp-5862 does not inhibit bcrp at clinically relevant concentrations. acalabrutinib does not inhibit mate1, while acp-5862 may increase exposure to co-administered mate1 substrates (e.g., metformin) by inhibition of mate1.

ommended single dose) with a high-fat, high-calorie meal (approximately 918 calories, 59 grams carbohydrate, 59 grams fat, and 39 grams protein) did not affect the mean auc as compared to dosing under fasted conditions. resulting c max decreased by 73% and t max was delayed 1-2 hours. distribution reversible binding to human plasma protein was 97.5% for acalabrutinib and 98.6% for acp-5862. the in vitro mean blood-to-plasma ratio was 0.8 for acalabrutinib and 0.7 for acp-5862. the geometric mean (% cv) steady-state volume of distribution (vss) was approximately 101 (52%) l for acalabrutinib and 67 (32%) l for acp-5862. elimination the geometric mean (% cv) terminal elimination half-life (t1/2) was 1 (59%) hour for acalabrutinib and 3.5 (24%) hours for acp-5862. the geometric mean (%cv) apparent oral clearance (cl/f) was 71 (35%) l/hr for acalabrutinib and 13 (42%) l/hr for acp-5862. metabolism acalabrutinib is predominantly metabolized by cyp3a enzymes, and to a minor extent, by glutathione conjugation and amide hydrolysis, based on in vitro studies. acp-5862 was identified as the major active metabolite in plasma with a geometric mean exposure (auc) that was approximately 2- to 3-fold higher than the exposure of acalabrutinib. acp-5862 is approximately 50% less potent than acalabrutinib with regard to btk inhibition. excretion following administration of a single 100 mg radiolabeled acalabrutinib dose in healthy subjects, 84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine, with less than 2% of the dose excreted as unchanged acalabrutinib in urine and feces. specific populations age, race, and body weight age (32 to 90 years), sex, race (caucasian, african american), and body weight (40 to 149 kg) did not have clinically meaningful effects on the pk of acalabrutinib and its active metabolite, acp-5862. renal impairment no clinically relevant pk difference was observed in patients with mild or moderate renal impairment (egfr ≥ 30 ml/min/1.73m2, as estimated by mdrd (modification of diet in renal disease equation)). acalabrutinib pk has not been evaluated in patients with severe renal impairment (egfr < 29 ml/min/1.73m2, mdrd) or renal impairment requiring dialysis. hepatic impairment the auc of acalabrutinib increased 1.9-fold in subjects with mild hepatic impairment (child-pugh class a), 1.5-fold in subjects with moderate hepatic impairment (child-pugh class b) and 5.3-fold in subjects with severe hepatic impairment (child-pugh class c) compared to subjects with normal liver function. no clinically relevant pk difference in acp-5862 was observed in subjects with severe hepatic impairment (child-pugh class c) compared to subjects with normal liver function. no clinically relevant pk differences in acalabrutinib and acp-5862 were observed in patients with mild or moderate hepatic impairment (total bilirubin less and equal to upper limit of normal [uln] and ast greater than uln, or total bilirubin greater than uln and any ast) relative to patients with normal hepatic function (total bilirubin and ast within uln). drug interaction studies effect of cyp3a inhibitors on acalabrutinib co-administration with a strong cyp3a inhibitor (200 mg itraconazole once daily for 5 days) increased the acalabrutinib c max by 3.9-fold and auc by 5.1-fold in healthy subjects. physiologically based pharmacokinetic (pbpk) simulations with acalabrutinib and moderate cyp3a inhibitors (erythromycin, fluconazole, diltiazem) showed that co-administration increased acalabrutinib c max and auc approximately 2- to 3-fold. effect of cyp3a inducers on acalabrutinib co-administration with a strong cyp3a inducer (600 mg rifampin once daily for 9 days) decreased acalabrutinib c max by 68% and auc by 77% in healthy subjects. gastric acid reducing agents acalabrutinib solubility decreases with increasing ph. co-administration with an antacid (1 g calcium carbonate) decreased acalabrutinib auc by 53% in healthy subjects. co-administration with a proton pump inhibitor (40 mg omeprazole for 5 days) decreased acalabrutinib auc by 43%. in vitro studies metabolic pathways acalabrutinib is a weak inhibitor of cyp3a4/5, cyp2c8 and cyp2c9, but does not inhibit cyp1a2, cyp2b6, cyp2c19, cyp2d6, ugt1a1, and ugt2b7. acp-5862 is a weak inhibitor of cyp2c8, cyp2c9 and cyp2c19, but does not inhibit cyp1a2, cyp2b6, cyp2d6, cyp3a4/5, ugt1a1, and ugt2b7. acalabrutinib is a weak inducer of cyp1a2, cyp2b6 and cyp3a4; acp-5862 weakly induces cyp3a4. based on in vitro data and pbpk modeling, no interaction with cyp substrates is expected at clinically relevant concentrations. drug transporter systems acalabrutinib and its active metabolite, acp-5862, are substrates of p-glycoprotein (p-gp) and breast cancer resistance protein (bcrp). acalabrutinib is not a substrate of renal uptake transporters oat1, oat3, and oct2, or hepatic transporters oatp1b1, and oatp1b3. acp-5862 is not a substrate of oatp1b1 or oatp1b3. acalabrutinib and acp-5862 do not inhibit p-gp, oat1, oat3, oct2, oatp1b1, oatp1b3, and mate2-k at clinically relevant concentrations. acalabrutinib may increase exposure to co-administered bcrp substrates (e.g., methotrexate) by inhibition of intestinal bcrp. acp-5862 does not inhibit bcrp at clinically relevant concentrations. acalabrutinib does not inhibit mate1, while acp-5862 may increase exposure to co-administered mate1 substrates (e.g., metformin) by inhibition of mate1.

seline lactate dehydrogenase and white cell count) was intermediate in 44% and high in 17% of patients. calquence was administered orally at 100 mg approximately every 12 hours until disease progression or unacceptable toxicity. the median dose intensity was 98.5%. the major efficacy outcome of trial ly-004 was overall response rate and the median follow-up was 15.2 months. table 9: efficacy results in patients with mcl in trial ly-004 investigator assessed n=124 independent review committee (irc) assessed n=124 overall response rate (orr) per 2014 lugano classification. orr (%) [95% ci] 81 [73, 87] 80 [72, 87] complete response (%) [95% ci] 40 [31, 49] 40 [31, 49] partial response (%) [95% ci] 41 [32, 50] 40 [32, 50] duration of response (dor) median dor in months [range] ne [1+ to 20+] ne [0+ to 20+] ci= confidence interval; ne=not estimable; + indicates censored observations the median time to best response was 1.9 months. lymphocytosis upon initiation of calquence, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count (alc) increased ≥ 50% from baseline and a post baseline assessment ≥ 5 x 10 9 ) in 31.5% of patients in trial ly-004. the median time to onset of lymphocytosis was 1.1 weeks and the median duration of lymphocytosis was 6.7 weeks. 14.2 chronic lymphocytic leukemia the efficacy of calquence in patients with cll was demonstrated in two randomized, controlled trials. the indication for calquence includes patients with sll because it is the same disease. elevate-tn the efficacy of calquence was evaluated in the elevate-tn trial, a randomized, multicenter, open-label, actively controlled, 3 arm trial of calquence in combination with obinutuzumab, calquence monotherapy, and obinutuzumab in combination with chlorambucil in 535 patients with previously untreated chronic lymphocytic leukemia (nct02475681). patients 65 years of age or older or between 18 and 65 years of age with a total cumulative illness rating scale (cirs) > 6 or creatinine clearance of 30 to 69 ml/min were enrolled. the trial also required hepatic transaminases ≤ 3 times upper limit of normal (uln) and total bilirubin ≤ 1.5 times uln, and excluded patients with richter’s transformation. patients were randomized in a 1:1:1 ratio into 3 arms to receive: • calquence plus obinutuzumab (calquence+g): calquence 100 mg was administered approximately every 12 hours starting on cycle 1 day 1 until disease progression or unacceptable toxicity. obinutuzumab was administered starting on cycle 2 day 1 for a maximum of 6 treatment cycles. obinutuzumab 1000 mg was administered on days 1 and 2 (100 mg on day 1 and 900 mg on day 2), 8 and 15 of cycle 2 followed by 1000 mg on day 1 of cycles 3 up to 7. each cycle was 28 days. • calquence monotherapy: calquence 100 mg was administered approximately every 12 hours until disease progression or unacceptable toxicity. • obinutuzumab plus chlorambucil (gclb): obinutuzumab and chlorambucil were administered for a maximum of 6 treatment cycles. obinutuzumab 1000 mg was administered intravenously on days 1 and 2 (100 mg on day 1 and 900 mg on day 2), 8 and 15 of cycle 1 followed by 1000 mg on day 1 of cycles 2 to 6. chlorambucil 0.5 mg/kg was administered orally on days 1 and 15 of cycles 1 to 6. each cycle was 28 days. randomization was stratified by 17p deletion mutation status, ecog performance status (0 or 1 versus 2), and geographic region. a total of 535 patients were randomized, 179 to calquence+g, 179 to calquence monotherapy, and 177 to gclb. the overall median age was 70 years (range: 41 to 91 years), 47% had rai stage iii or iv disease, 14% had 17p deletion or tp53 mutation, 63% of patients had an unmutated igvh, and 18% had 11q deletion. baseline demographic and disease characteristics were similar between treatment arms. efficacy was based on progression-free survival (pfs) as assessed by an independent review committee (irc). the median duration of follow-up was 28.3 months (range: 0.0 to 40.8 months). efficacy results are presented in table 10. the kaplan-meier curves for pfs are shown in figure 1. table 10: efficacy results per irc in patients with cll -- itt population (elevate-tn) calquence plus obinutuzumab n=179 calquence monotherapy n=179 obinutuzumab plus chlorambucil n=177 progression-free survival per 2008 international workshop on cll (iwcll) criteria. number of events (%) 14 (8) 26 (15) 93 (53) pd, n (%) 9 (5) 20 (11) 82 (46) death events, n (%) 5 (3) 6 (3) 11 (6) median (95% ci), months kaplan-meier estimate. ne ne (34, ne) 22.6 (20, 28) hr based on a stratified cox-proportional-hazards model. both hazard ratios are compared with the obinutuzumab and chlorambucil arm. (95% ci) 0.10 (0.06, 0.17) 0.20 (0.13, 0.30) - p-value based on a stratified log-rank test, with an alpha level of 0.012 derived from alpha spending function by the o’brien-fleming method. < 0.0001 < 0.0001 - overall response rate (cr + cri + npr + pr) orr, n (%) 168 (94) 153 (86) 139 (79) (95% ci) (89, 97) (80, 90) (72, 84) p-value based on a stratified cochran–mantel–haenszel test, for the comparison with the obinutuzumab and chlorambucil arm. < 0.0001 0.0763 - cr, n (%) 23 (13) 1 (1) 8 (5) cri, n (%) 1 (1) 0 0 npr, n (%) 1 (1) 2 (1) 3 (2) pr, n (%) 143 (80) 150 (84) 128 (72) itt=intent-to-treat; ci=confidence interval; hr=hazard ratio; ne=not estimable; cr=complete response; cri=complete response with incomplete blood count recovery; npr=nodular partial response; pr=partial response. figure 1: kaplan-meier curve of irc-assessed pfs in patients with cll in elevate-tn with a median follow-up of 28.3 months, median overall survival was not reached in any arm, with fewer than 10% of patients experiencing an event. ascend the efficacy of calquence in patients with relapsed or refractory cll was based upon a multicenter, randomized, open-label trial (ascend; nct02970318). the trial enrolled 310 patients with relapsed or refractory cll after at least 1 prior systemic therapy. the trial excluded patients with transformed disease, prolymphocytic leukemia, or previous treatment with venetoclax, a bruton tyrosine kinase inhibitor, or a phosphoinositide-3 kinase inhibitor. patients were randomized in a 1:1 ratio to receive either: • calquence 100 mg approximately every 12 hours until disease progression or unacceptable toxicity, or • investigator’s choice: • idelalisib plus a rituximab product (ir): idelalisib 150 mg orally approximately every 12 hours until disease progression or unacceptable toxicity, in combination with 8 infusions of a rituximab product (375 mg/m2 intravenously on day 1 of cycle 1, followed by 500 mg/m2 every 2 weeks for 4 doses and then every 4 weeks for 3 doses), with a 28-day cycle length. • bendamustine plus a rituximab product (br): bendamustine 70 mg/m2 intravenously (day 1 and 2 of each 28-day cycle), in combination with a rituximab product (375 mg/m2 intravenously on day 1 of cycle 1, then 500 mg/m2 on day 1 of subsequent cycles), for up to 6 cycles. randomization was stratified by 17p deletion mutation status, ecog performance status (0 or 1 versus 2), and number of prior therapies (1 to 3 versus ≥ 4). of 310 patients total, 155 were assigned to calquence monotherapy, 119 to ir, and 36 to br. the median age overall was 67 years (range: 32 to 90 years), 42% had rai stage iii or iv disease, 28% had 17p deletion or tp53 mutation, 78% of patients had an unmutated igvh, and 27% had a 11q deletion. the calquence arm had a median of 1 prior therapy (range 1-8), with 47% having at least 2 prior therapies. the investigator’s choice arm had a median of 2 prior therapies (range 1-10), with 57% having at least 2 prior therapies. in the calquence arm, the median treatment duration was 15.7 months, with 94% of patients treated for at least 6 months and 86% of patients treated for at least 1 year. in the investigator’s choice arm, the median treatment duration was 8.4 months, with 59% of patients treated for at least 6 months and 37% treated for at least 1 year. efficacy was based on pfs as assessed by an irc, with a median follow-up of 16.1 months (range 0.03 to 22.4 months). efficacy results are presented in table 11. the kaplan-meier curve for pfs is shown in figure 2. there was no statistically significant difference in overall response rates between the two treatment arms. table 11: efficacy results per irc in patients with relapsed or refractory cll – itt population (ascend) calquence monotherapy n=155 investigator’s choice of idelalisib + rituximab product or bendamustine + rituximab product n=155 progression-free survival per 2008 iwcll criteria. number of events, n (%) 27 (17) 68 (44) disease progression, n 19 59 death, n 8 9 median (95% ci), months kaplan-meier estimate ne (ne, ne) 16.5 (14.0, 17.1) hr (95% ci) based on a stratified cox-proportional-hazards model 0.31 (0.20, 0.49) p-value based on a stratified log-rank test. the pre-specified type i error rate (α) for this interim analysis is 0.012 derived from a lan-demets alpha spending function with o’brien-fleming boundary < 0.0001 overall response rate (cr + cri + npr + pr) through a hierarchical testing procedure, the difference in orr was not statistically significant, based on a cochran-mantel haenzel test with adjustment for randomization stratification factors. orr, n (%) 126 (81) 117 (75) (95% ci) (74, 87) (68, 82) cr, n (%) 0 2 (1) cri, n (%) 0 0 npr, n (%) 0 0 pr, n (%) 126 (81) 115 (74) itt=intent-to-treat; ci=confidence interval; hr=hazard ratio; ne=not estimable; cr=complete response; cri=complete response with incomplete blood count recovery; npr=nodular partial response; pr=partial response figure 2: kaplan-meier curve of irc-assessed pfs in patients with cll in ascend with a median follow up of 16.1 months, median overall survival was not reached in either arm, with fewer than 11% of patients experiencing an event. figure 1 figure 2

, dizziness, fainting, chest discomfort, and shortness of breath [see warnings and precautions (5.5) ] . pregnancy complication calquence may cause fetal harm and dystocia. advise women to avoid becoming pregnant during treatment and for at least 1 week after the last dose of calquence [see use in specific populations (8.3) ] . lactation advise females not to breastfeed during treatment with calquence and for at least 2 weeks after the final dose [see use in specific populations (8.2) ] . dosing instructions instruct patients to take calquence orally twice daily, about 12 hours apart. calquence may be taken with or without food. advise patients that calquence capsules should be swallowed whole with a glass of water, without being opened, broken, or chewed [see dosage and administration (2.1) ] . missed dose advise patients that if they miss a dose of calquence, they may still take it up to 3 hours after the time they would normally take it. if more than 3 hours have elapsed, they should be instructed to skip that dose and take their next dose of calquence at the usual time. warn patients they should not take extra capsules to make up for the dose that they missed [see dosage and administration (2.1) ] . drug interactions advise patients to inform their healthcare providers of all concomitant medications, including over-the-counter medications, vitamins and herbal products [see drug interactions (7) ] . distributed by: astrazeneca pharmaceuticals lp wilmington, de 19850 calquence is a registered trademark of the astrazeneca group of companies. ©astrazeneca 2019

me pregnant, your healthcare provider may do a pregnancy test before you start treatment with calquence • females who are able to become pregnant should use effective birth control (contraception) during treatment with calquence and for at least 1 week after the last dose of calquence. • are breastfeeding or plan to breastfeed. it is not known if calquence passes into your breast milk. do not breastfeed during treatment with calquence and for at least 2 weeks after your final dose of calquence. tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. taking calquence with certain other medications may affect how calquence works and can cause side effects. especially tell your healthcare provider if you take a blood thinner medicine. how should i take calquence? • take calquence exactly as your healthcare provider tells you to take it. • do not change your dose or stop taking calquence unless your healthcare provider tells you to. • your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking calquence if you develop certain side effects. • take calquence 2 times a day (about 12 hours apart). • take calquence with or without food. • swallow calquence capsules whole with a glass of water. do not open, break, or chew capsules. • if you need to take an antacid medicine, take it either 2 hours before or 2 hours after you take calquence. • if you need to take certain other medicines called acid reducers (h-2 receptor blockers), take calquence 2 hours before the acid reducer medicine. • if you miss a dose of calquence, take it as soon as you remember. if it is more than 3 hours past your usual dosing time, skip the missed dose and take your next dose of calquence at your regularly scheduled time. do not take an extra dose to make up for a missed dose. what are the possible side effects of calquence? calquence may cause serious side effects, including: • serious infections can happen during treatment with calquence and may lead to death. your healthcare provider may prescribe certain medicines if you have an increased risk of getting infections. tell your healthcare provider right away if you have any signs or symptoms of an infection, including fever, chills, or flu-like symptoms. • bleeding problems (hemorrhage) can happen during treatment with calquence and can be serious and may lead to death. your risk of bleeding may increase if you are also taking a blood thinner medicine. tell your healthcare provider if you have any signs or symptoms of bleeding, including: • blood in your stools or black stools (looks like tar) • pink or brown urine • unexpected bleeding, or bleeding that is severe or you cannot control • vomit blood or vomit that looks like coffee grounds • cough up blood or blood clots • dizziness • weakness • confusion • changes in your speech • headache that lasts a long time • bruising or red or purple skin marks • decrease in blood cell counts. decreased blood counts (white blood cells, platelets, and red blood cells) are common with calquence, but can also be severe. your healthcare provider should do blood tests to check your blood counts regularly during treatment with calquence. • second primary cancers. new cancers have happened in people during treatment with calquence, including cancers of the skin or other organs. your healthcare provider will check you for skin cancers during treatment with calquence. use sun protection when you are outside in sunlight. • heart rhythm problems (atrial fibrillation and atrial flutter) have happened in people treated with calquence. tell your healthcare provider if you have any of the following signs or symptoms: • fast or irregular heartbeat • dizziness • feeling faint • chest discomfort • shortness of breath the most common side effects of calquence include: • headache • diarrhea • muscle and joint pain • upper respiratory tract infection • bruising these are not all of the possible side effects of calquence. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store calquence? • store calquence at room temperature between 68°f to 77°f (20°c to 25°c). keep calquence and all medicines out of the reach of children. general information about the safe and effective use of calquence. medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. do not use calquence for a condition for which it was not prescribed. do not give calquence to other people, even if they have the same symptoms you have. it may harm them. you can ask your healthcare provider or pharmacist for more information about calquence that is written for health professionals. what are the ingredients in calquence? active ingredient: acalabrutinib inactive ingredients: silicified microcrystalline cellulose, pregelatinized starch, magnesium stearate, and sodium starch glycolate. capsule shell contains: gelatin, titanium dioxide, yellow iron oxide, fd&c blue 2, and black ink. distributed by: astrazeneca pharmaceuticals lp, wilmington, de 19850 calquence is a registered trademark of the astrazeneca group of companies. ©astrazeneca xxxx for more information, go to www.calquence.com or call 1-800-236-9933. this patient information has been approved by the u.s. food and drug administration. revised: 11/2019